SFM
PSTX

Sphera Funds Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Sphera Funds Management’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-300,000
Closed -$1.06M – 89
2022
Q3 		$1.06M Buy
+300,000
New +$992K 0.15% 62

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Sphera Funds Management's PSTX Position: Q4 2022 in Review

Sphera Funds Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2022, closing a stake of 300,000 shares — an estimated $1.06M sold.

Sphera Funds Management first reported a position in PSTX in Q3 2022 and held it in 1 quarter. The position peaked at $1.06M in Q3 2022. 89 funds tracked by Wall St. Rank hold PSTX as of Q4 2022.

  • Sphera Funds Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Sphera Funds Management sold 300,000 Poseida Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1.06M.
  • Sphera Funds Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Sphera Funds Management's Poseida Therapeutics, Inc. Common Stock position peaked at $1.06M in Q3 2022.
  • 89 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Sphera Funds Management's 13F filing for Q4 2022, filed 14 Feb 2023.